Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors - Singapore Investor
{{banner.link_text}}
For investors in Singapore

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies

ISIN
IE0009355771

NAV
USD 50.13
As of 2025/04/24

1-Day Change
USD 0.78 (1.58%)
 As of 2025/04/24

Morningstar Rating

As of 2025/03/31

Overview

OBJECTIVE AND INVESTMENT POLICY

The Fund aims to provide capital growth over the long term.

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care

Portfolio Management

Andy Acker, CFA: Portfolio Manager
Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA: Portfolio Manager | Research Analyst
Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative & Annualised Performance (%)
As of 2025/03/31
A2 USD (With Sales Charge)* MSCI World Health Care NR Sector Equity Healthcare - OE A2 USD (Net)
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
2000/03/31
A2 USD (With Sales Charge)* -9.40 -4.52 -15.57 -4.52 -10.13 1.19 8.10 4.82 6.57
MSCI World Health Care NR -2.32 5.10 -6.88 5.10 -1.10 2.58 9.89 7.01 7.42
Sector Equity Healthcare - OE -3.57 1.43 -8.75 1.43 -3.67 -1.16 5.41 3.84 5.80
A2 USD (Net) -4.63 0.51 -11.13 0.51 -5.40 2.93 9.22 5.36 6.79
Past performance is not a guide to future performance. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
*Performance with sales charge assume 5.00% initial sales charge/front-end load (FEL) applied.
© Morningstar 2025. All rights reserved. NAV-NAV, gross income reinvested where applicable.

Recommended holding period 5 Years

Example Investment: USD 10,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs1,360 USD1,420 USD
Average return each year-86.43%-32.36%
UnfavourableWhat you might get back after costs7,630 USD10,310 USD
Average return each year-23.73%0.61%
ModerateWhat you might get back after costs10,490 USD14,840 USD
Average return each year4.93%8.21%
FavourableWhat you might get back after costs13,220 USD19,520 USD
Average return each year32.19%14.31%
There is currently insufficient data to provide a useful indication of past performance to investors.
Fee Information
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2023/12/31) 		2.38%

Portfolio

Top Holdings (As of 2025/03/31)
% of Fund
Eli Lilly & Co 9.41
UnitedHealth Group Inc 6.87
AstraZeneca PLC 4.00
Johnson & Johnson 3.59
Boston Scientific Corp 3.13
Abbott Laboratories 3.09
Sanofi SA 3.06
Amgen Inc 2.89
AbbVie Inc 2.83
Vertex Pharmaceuticals Inc 2.82
TOTAL 41.69
Sector Allocation % of Fund % of Index % of Fund % of Index As of 2025/03/31
Regional Allocation % of Fund % of Index % of Fund % of Index As of 2025/03/31

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Global Perspectives: What’s next for booming weight-loss drugs
Mar 20, 2025
Features & Outlooks

Global Perspectives: What’s next for booming weight-loss drugs

New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.

17 min read

The case for healthcare stocks amid political uncertainty
Mar 18, 2025
Timely & Topical

The case for healthcare stocks amid political uncertainty

The sector offers both traditionally defensive holdings and long-term growth potential that now looks attractively valued.

5 min read

JH Explorer: Takeaways from the 2025 J.P. Morgan Healthcare Conference
Feb 4, 2025
Timely & Topical

JH Explorer: Takeaways from the 2025 J.P. Morgan Healthcare Conference

After attending the sector’s preeminent annual gathering, we are as confident as ever in healthcare’s long-term value.

4 min read

Choose region

Country

Language

What type of investor are you?